Table 1.
Delay-adjusted incidence rates and fixed-interval trends for 2009 to 2013 for the most common cancers by sex, race, and ethnicity, for areas in the United States with high-quality incidence data*
| Sex/cancer site or type† | White‡ |
Black‡ |
API‡ |
AI/AN (CHSDA)‡ |
Hispanic‡ |
Non-Hispanic‡ |
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rank | Rate§ | AAPC‖ | P# | Rank | Rate§ | AAPC‖ | P# | Rank | Rate§ | AAPC‖ | P# | Rank | Rate§ | AAPC‖ | P# | Rank | Rate§ | AAPC‖ | P# | Rank | Rate§ | AAPC‖ | P# | |
| All sites¶ | ||||||||||||||||||||||||
| Both sexes | 461.7 | −1.1 | .007 | 474.4 | −1.4 | .001 | 302.1 | −0.4 | <.001 | 420.2 | 0.0 | .76 | 362.1 | −0.7 | <.001 | 469.8 | −1.1 | <.001 | ||||||
| Males | 511.2 | −2.2 | <.001 | 576.2 | −3.1 | <.001 | 318.2 | −1.2 | <.001 | 445.1 | −0.6 | .03 | 407.0 | −2.8 | <.001 | 525.5 | −2.2 | <.001 | ||||||
| Females | 427.5 | 0.0 | .60 | 406.1 | 0.3 | <.001 | 294.3 | 0.7 | <.001 | 405.9 | 0.6 | .002 | 334.8 | −0.1 | .05 | 430.2 | 0.0 | .53 | ||||||
| Males | ||||||||||||||||||||||||
| Prostate | 1 | 118.0 | −6.9 | .001 | 1 | 205.3 | −6.0 | .001 | 1 | 68.1 | −7.5 | .005 | 1 | 93.4 | −9.0 | .01 | 1 | 110.1 | −7.9 | <.001 | 1 | 128.4 | −7.8 | .004 |
| Lung and bronchus | 2 | 74.8 | −2.6 | <.001 | 2 | 88.2 | −3.4 | <.001 | 2 | 48.0 | −1.3 | <.001 | 2 | 73.9 | −0.5 | .25 | 3 | 43.2 | −2.5 | <.001 | 2 | 77.9 | −2.5 | <.001 |
| Colon and rectum | 3 | 46.5 | −3.3 | <.001 | 3 | 58.0 | −2.7 | <.001 | 3 | 39.0 | −2.2 | <.001 | 3 | 54.2 | −0.7 | .17 | 2 | 44.2 | −3.0 | <.001 | 3 | 48.0 | −3.2 | <.001 |
| Urinary bladder | 4 | 39.6 | −0.5 | <.001 | 5 | 20.3 | 0.7 | <.001 | 6 | 15.9 | −0.3 | .15 | 5 | 21.2 | 0.1 | .81 | 5 | 20.8 | −1.9 | <.001 | 4 | 38.7 | −0.4 | <.001 |
| Melanoma of the skin | 5 | 30.4 | 2.5 | <.001 | 19 | 1.1 | −0.6 | .32 | 18 | 1.5 | −0.4 | .47 | 12 | 8.9 | 2.0 | .03 | 14 | 5.4 | 1.0 | .15 | 5 | 29.2 | 2.5 | <.001 |
| Non-Hodgkin lymphoma | 6 | 24.5 | −0.4 | .02 | 6 | 17.7 | 0.2 | .25 | 5 | 16.3 | 0.3 | .25 | 7 | 18.4 | 0.1 | .87 | 6 | 20.8 | −0.1 | .64 | 6 | 24.1 | −0.6 | .05 |
| Kidney and renal pelvis | 7 | 22.4 | 0.6 | .005 | 4 | 24.4 | 0.8 | .13 | 9 | 11.3 | 2.7 | <.001 | 4 | 31.7 | 2.1 | .005 | 4 | 21.5 | 0.8 | .23 | 7 | 22.4 | 0.9 | .10 |
| Leukemia | 8 | 19.5 | 2.0 | <.001 | 12 | 14.6 | 1.1 | <.001 | 10 | 10.4 | 0.1 | .97 | 9 | 12.7 | −0.5 | .60 | 8 | 14.1 | 0.5 | .03 | 8 | 19.1 | 1.8 | <.001 |
| Oral cavity and pharynx | 9 | 18.0 | 1.7 | <.001 | 10 | 15.0 | −2.0 | <.001 | 8 | 11.3 | 0.3 | .36 | 8 | 16.5 | 1.1 | .21 | 11 | 11.2 | −0.7 | .02 | 9 | 18.3 | 1.5 | <.001 |
| Pancreas | 10 | 14.2 | 1.1 | <.001 | 8 | 17.0 | 0.5 | .01 | 11 | 10.4 | 0.7 | .01 | 10 | 11.6 | 0.7 | .53 | 10 | 12.4 | 0.6 | .02 | 10 | 14.5 | 1.1 | <.001 |
| Liver and intrahepatic bile duct | 11 | 11.0 | 4.2 | <.001 | 7 | 17.3 | 3.1 | <.001 | 4 | 21.1 | −0.4 | .10 | 6 | 18.9 | 3.6 | <.001 | 7 | 20.1 | 0.2 | .81 | 11 | 11.4 | 4.0 | <.001 |
| Stomach | 12 | 8.6 | 0.1 | .78 | 11 | 14.7 | −1.8 | <.001 | 7 | 14.7 | −2.9 | <.001 | 11 | 11.5 | −2.3 | .03 | 9 | 13.4 | −2.2 | <.001 | 12 | 9.0 | 0.0 | .99 |
| Myeloma | 15 | 7.9 | 2.6 | <.001 | 9 | 16.5 | 2.2 | <.001 | 13 | 5.1 | 2.6 | <.001 | 13 | 8.0 | 1.5 | .24 | 12 | 8.4 | 1.6 | <.001 | 14 | 8.6 | 2.6 | <.001 |
| Esophagus | 13 | 8.6 | −1.8 | .006 | 14 | 7.3 | −4.7 | <.001 | 15 | 3.6 | −1.4 | .05 | 14 | 7.6 | −1.7 | .21 | 17 | 5.1 | −3.8 | .003 | 13 | 8.6 | −1.9 | .001 |
| Brain and other nervous system | 14 | 8.5 | −0.1 | .07 | 15 | 4.9 | 0.4 | .11 | 14 | 4.4 | 0.3 | .36 | 15 | 5.9 | 1.2 | .30 | 13 | 6.1 | −0.5 | .006 | 15 | 8.3 | 0.0 | .68 |
| Thyroid | 16 | 7.6 | 2.6 | .008 | 16 | 3.8 | 4.9 | <.001 | 12 | 6.9 | 5.9 | <.001 | 18 | 4.3 | 3.5 | .05 | 15 | 5.3 | 4.6 | <.001 | 16 | 7.5 | 2.7 | .003 |
| Larynx | 18 | 6.1 | −2.0 | <.001 | 13 | 8.6 | −3.3 | <.001 | 16 | 2.3 | −2.9 | .002 | 17 | 5.3 | −1.9 | .07 | 16 | 5.2 | −2.9 | <.001 | 17 | 6.4 | −2.1 | <.001 |
| <.001 | ||||||||||||||||||||||||
| Females | <.001 | |||||||||||||||||||||||
| Breast | 1 | 126.9 | 0.3 | .08 | 1 | 125.3 | 1.2 | <.001 | 1 | 93.4 | 1.9 | <.001 | 1 | 105.4 | 3.6 | .05 | 1 | 95.6 | 0.4 | .06 | 1 | 129.1 | 0.5 | .01 |
| Lung and bronchus | 2 | 55.7 | −1.1 | <.001 | 2 | 50.7 | −0.7 | .006 | 2 | 28.9 | 0.4 | .01 | 2 | 58.3 | −1.7 | .02 | 3 | 26.1 | −0.7 | .001 | 2 | 56.7 | −1.1 | <.001 |
| Colon and rectum | 3 | 35.2 | −2.8 | <.001 | 3 | 42.5 | −3.1 | <.001 | 3 | 28.7 | −4.6 | <.001 | 3 | 43.7 | −1.0 | .02 | 2 | 30.6 | −2.8 | <.001 | 3 | 36.5 | −2.9 | <.001 |
| Corpus and uterus, NOS | 4 | 26.6 | 1.1 | <.001 | 4 | 25.3 | 2.3 | <.001 | 5 | 18.8 | 2.3 | <.001 | 4 | 23.9 | 1.7 | .002 | 4 | 22.4 | 2.9 | <.001 | 4 | 26.4 | 1.1 | <.001 |
| Thyroid | 5 | 22.4 | 2.1 | <.001 | 6 | 13.7 | 6.4 | <.001 | 4 | 21.5 | 3.1 | <.001 | 7 | 14.8 | 5.7 | <.001 | 5 | 20.0 | 2.7 | .02 | 5 | 21.6 | 3.1 | <.001 |
| Melanoma of the skin | 6 | 19.4 | 1.2 | .004 | 21 | 1.0 | 0.7 | .18 | 18 | 1.2 | −1.1 | .14 | 15 | 6.3 | 1.9 | .04 | 17 | 4.5 | 0.6 | .36 | 6 | 18.3 | 1.1 | .008 |
| Non-Hodgkin lymphoma | 7 | 17.0 | −0.6 | .005 | 8 | 12.4 | 0.7 | .001 | 6 | 11.0 | 0.0 | .96 | 6 | 14.8 | 0.3 | .63 | 6 | 15.8 | 0.1 | .50 | 7 | 16.5 | −0.5 | .003 |
| Ovary | 8 | 12.4 | −1.6 | <.001 | 11 | 9.7 | −0.5 | .01 | 7 | 9.4 | −0.4 | .12 | 8 | 11.6 | −0.6 | .53 | 8 | 10.7 | −1.3 | <.001 | 8 | 12.1 | −1.6 | <.001 |
| Kidney and renal pelvis | 10 | 11.6 | 0.4 | .12 | 7 | 12.8 | 0.0 | .98 | 14 | 5.1 | −1.3 | .30 | 5 | 18.9 | 2.0 | .007 | 7 | 12.4 | 2.2 | <.001 | 10 | 11.4 | −0.2 | .28 |
| Leukemia | 9 | 11.9 | 1.6 | <.001 | 12 | 9.4 | 2.5 | <.001 | 11 | 6.7 | 1.2 | .003 | 10 | 10.2 | 1.1 | .22 | 11 | 9.6 | 0.4 | .07 | 9 | 11.5 | 1.8 | .001 |
| Pancreas | 11 | 10.8 | 1.1 | <.001 | 5 | 14.4 | 0.7 | <.001 | 8 | 9.0 | 0.9 | .005 | 9 | 10.3 | 0.3 | .77 | 9 | 10.5 | 0.6 | <.001 | 11 | 11.2 | 1.1 | <.001 |
| Urinary bladder | 12 | 9.7 | −0.7 | <.001 | 14 | 6.8 | −0.3 | .26 | 15 | 3.9 | −0.5 | .35 | 13 | 6.7 | 2.3 | .02 | 15 | 5.3 | −1.3 | .002 | 12 | 9.5 | −0.7 | <.001 |
| Cervix Uteri | 13 | 7.5 | −0.9 | <.001 | 10 | 9.7 | −3.7 | .008 | 12 | 6.3 | −2.9 | <.001 | 11 | 10.1 | −5.3 | .22 | 10 | 10.0 | −3.8 | <.001 | 13 | 7.4 | −1.9 | .003 |
| Oral cavity and pharynx | 14 | 6.6 | 1.0 | <.001 | 15 | 5.3 | −0.8 | .002 | 13 | 5.2 | 3.5 | .14 | 17 | 6.2 | 0.6 | .65 | 18 | 4.3 | −1.7 | .18 | 14 | 6.7 | 0.9 | <.001 |
| Brain and other nervous system | 15 | 6.2 | −0.6 | .07 | 17 | 3.7 | 0.0 | .85 | 17 | 3.2 | 2.2 | .14 | 18 | 3.7 | −0.2 | .91 | 16 | 4.7 | −1.1 | <.001 | 15 | 5.9 | −0.5 | .11 |
| Myeloma | 16 | 4.9 | 2.4 | <.001 | 9 | 12.3 | 3.6 | <.001 | 16 | 3.2 | 0.7 | .24 | 16 | 6.3 | −1.2 | .34 | 14 | 5.6 | 0.4 | .11 | 16 | 5.6 | 2.1 | <.001 |
| Stomach | 17 | 4.1 | 0.7 | .36 | 13 | 8.1 | −1.2 | <.001 | 9 | 8.6 | −2.5 | <.001 | 14 | 6.7 | −1.4 | .15 | 12 | 8.0 | −1.6 | <.001 | 17 | 4.4 | −0.9 | <.001 |
| Liver and intrahepatic bile duct | 18 | 3.8 | 4.3 | <.001 | 16 | 5.1 | 3.7 | <.001 | 10 | 7.8 | −2.6 | .03 | 12 | 9.1 | 3.8 | .006 | 13 | 7.6 | 2.2 | <.001 | 18 | 3.9 | 3.6 | <.001 |
Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results areas reported by the North American Association of Central Cancer Registries as meeting high-quality incidence data standards for the specified time periods. AAPC = average annual percent change; AI/AN = American Indian/Alaska Native; APC = annual percent change; API = Asian/Pacific Islander; CHSDA = IHS Contract Health Services Delivery Area; IHS = Indian Health Service; NAACCR = North American Association of Central Cancer Registries; NOS = not otherwise specified; NPCR = National Program of Cancer Registries; SEER = Surveillance, Epidemiology, and End Results.
Cancers are sorted in descending order according to sex-specific rates for all races/ethnicities. More than 15 cancers may appear under males and females to include the top 15 cancers in every race/ethnicity group.
White, black, API, and AI/AN (CHSDA 2012 counties) include Hispanic and non-Hispanic; the race and ethnicity categories are not mutually exclusive. AI/AN (CHSDA 2012) statistics exclude data from Kansas.
Rates are per 100 000 persons and were age-standardized to the 2000 US standard population (19 age groups Census P25–1130).
AAPC is the average annual percent change and is a weighted average of the annual percent change (APC) over the fixed interval 2009 to 2013 using the underlying joinpoint model for the period of 1999 to 2013. Joinpoint models with up to two joinpoints are based on rates per 100 000 persons that are age-standardized to the 2000 US standard population (19 age groups Census P25–1130). Joinpoint Regression Program, version 4.2.0.2. June 2015, Statistical Research and Applications Branch, National Cancer Institute.
Registries included in the incidence rates (2009–2013) and joinpoint models (1999–2013) for all races/ethnicities, white, black, AI/AN, API, Hispanic, and non-Hispanic (41 states): Alabama, Alaska, Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Missouri, Montana, Nebraska, New Hampshire, New Jersey, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, Texas, Utah, Vermont, Washington, West Virginia, Wisconsin, Wyoming.
For all sites, myelodysplastic syndromes are included for the rate calculations but not for the APC calculations; they are excluded from cancer-specific analysis. Ovary excludes borderline tumors.
AAPC two-sided P value based on t distribution if AAPC interval within one segment; otherwise, AAPC two-sided P value based on normal distribution.